Retatrutide: How to Get It and What You Should Know

Retatrutide is generating enormous interest as a potential next-generation weight loss medication. As a triple-agonist peptide that targets three key hormone pathways involved in appetite, metabolism, and energy regulation, it represents a significant leap forward from current medical weight loss programs. Early clinical trial data showing participants losing up to 24% of their body weight has made it one of the most anticipated medications in the obesity treatment space.

If you are researching retatrutide, you likely have questions about how to access it, what the clinical evidence actually shows, how it compares to existing treatments, and what you should know before considering this therapy. This comprehensive guide addresses all of those questions with current, evidence-based information.

What Is Retatrutide?

Retatrutide (also known by its development name LY3437943) is an investigational medication developed by Eli Lilly and Company. It belongs to a new class of drugs called triple hormone receptor agonists, meaning it simultaneously activates three distinct receptor pathways:

The Three Receptor Targets

GLP-1 (Glucagon-Like Peptide-1) Receptor: This is the same receptor targeted by semaglutide (Ozempic, Wegovy) and is responsible for appetite suppression, delayed gastric emptying, and improved insulin secretion. GLP-1 activation reduces hunger, promotes feelings of fullness, and helps regulate blood sugar.

GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor: This receptor is also targeted by tirzepatide (Mounjaro, Zepbound). GIP activation enhances insulin sensitivity, supports fat metabolism, and may improve how the body processes and stores nutrients. Research in Cell Metabolism has shown that GIP signaling plays a critical role in adipose tissue function and energy homeostasis (Campbell & Drucker, 2015).

Glucagon Receptor: This is the unique receptor that sets retatrutide apart from all currently available weight loss medications. Glucagon activation increases hepatic glucose output, stimulates thermogenesis (heat production), and promotes lipolysis (fat breakdown). A review published in Diabetes, Obesity and Metabolism described glucagon receptor agonism as a mechanism that directly increases energy expenditure, meaning the body burns more calories at rest (Pocai, 2014).

The combination of all three pathways creates what researchers describe as a comprehensive metabolic reset — simultaneously reducing caloric intake through appetite suppression, improving how the body processes nutrients, and increasing the rate at which the body burns stored fat.

What Does the Clinical Evidence Show?

Phase 2 Trial Results

The pivotal Phase 2 clinical trial results for retatrutide were published in The New England Journal of Medicine in June 2023 and generated significant attention from the medical community and general public (Jastreboff et al., 2023).

Key findings from this 48-week, dose-ranging study of 338 adults with obesity:

• Participants receiving the highest dose (12 mg weekly) lost an average of 24.2% of their body weight in 48 weeks
• At the 12 mg dose, 100% of participants lost at least 5% of their body weight
• Approximately 83% of participants on the highest dose lost 15% or more of body weight
• The weight loss trajectory had not plateaued at 48 weeks, suggesting even greater weight loss with continued treatment

To put these numbers in context, here is how retatrutide’s Phase 2 data compares to the landmark trials of existing medications:

Medication	Receptors Targeted	Weight Loss	Trial Duration
Semaglutide 2.4 mg (STEP 1)	GLP-1	14.9%	68 weeks
Tirzepatide 15 mg (SURMOUNT-1)	GLP-1 + GIP	22.5%	72 weeks
Retatrutide 12 mg (Phase 2)	GLP-1 + GIP + Glucagon	24.2%	48 weeks

The fact that retatrutide achieved the highest percentage of weight loss in the shortest timeframe is what has researchers and patients so excited. However, it is important to note that Phase 2 trials are smaller and designed primarily to establish dosing and safety, not to provide definitive efficacy data.

Phase 2 Results in Type 2 Diabetes

A separate Phase 2 study examined retatrutide in adults with type 2 diabetes and obesity. Results published in The Lancet showed significant improvements in both weight and glycemic control (Rosenstock et al., 2023):

• Participants lost up to 16.9% of body weight (lower than the non-diabetic cohort, consistent with other medication studies)
• HbA1c reductions of up to 2.02 percentage points, bringing many participants into the normal range
• Significant improvements in fasting glucose and insulin sensitivity

Phase 3 Trials

Eli Lilly initiated Phase 3 clinical trials for retatrutide in late 2023. These larger, longer-duration studies will provide the comprehensive safety and efficacy data needed for FDA review. The Phase 3 program includes trials in obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH).

How to Get Retatrutide Right Now

As of early 2026, retatrutide is not yet FDA-approved and is not available through standard prescription channels. There are several pathways that patients may encounter, each with different levels of legitimacy and safety.

Clinical Trial Participation

The most legitimate way to access retatrutide is through enrollment in an active clinical trial. Eli Lilly’s Phase 3 trials are being conducted at research sites across the United States and internationally. ClinicalTrials.gov lists active studies and enrollment criteria.

Eligibility for clinical trials typically requires:

• BMI of 30 or greater, or BMI of 27 or greater with weight-related comorbidities
• No recent use of other weight loss medications (washout periods apply)
• Willingness to attend regular study visits and follow protocols
• Meeting specific inclusion/exclusion criteria that vary by trial

Compounding Pharmacies

Some compounding pharmacies have begun offering retatrutide. However, this is a gray area legally and medically. Unlike semaglutide and tirzepatide, which are FDA-approved medications that can be legally compounded during shortages, retatrutide has no FDA-approved version. The regulatory framework for compounding an unapproved medication is complex and varies by jurisdiction.

If you encounter compounded retatrutide, proceed with caution and work only with a trusted medical provider who can verify the source, purity, and dosing.

Research Chemical Sources

Numerous online vendors sell retatrutide as a “research chemical” not intended for human consumption. These products carry significant risks including unknown purity, incorrect dosing, contamination, and no medical oversight. The FDA has issued warnings about purchasing peptides from unregulated online sources.

We strongly advise against purchasing retatrutide from unregulated online sources.

Be Careful Where You Get Your Information

The excitement surrounding retatrutide has created a surge in misinformation, unverified claims, and predatory marketing. When evaluating information about retatrutide, consider the following:

• Verify the source. Rely on peer-reviewed journals (NEJM, The Lancet, JAMA), official clinical trial registries (ClinicalTrials.gov), and communications from Eli Lilly.
• Be skeptical of miracle claims. While the Phase 2 data is genuinely impressive, individual results will vary, and Phase 3 data may show different outcomes than Phase 2.
• Avoid unregulated products. Products sold as “retatrutide” online may not contain what they claim, may be impure, or may be incorrectly dosed.
• Work with qualified providers. A licensed medical provider can help you evaluate the legitimacy of any access pathway and monitor your health if you do obtain treatment.

Side Effects Reported in Clinical Trials

The Phase 2 trials provided initial safety data for retatrutide. Like other incretin-based medications, the most common side effects were gastrointestinal:

Common Side Effects

• Nausea: Reported in approximately 25-45% of participants depending on dose (most common during titration)
• Diarrhea: Approximately 20-35% of participants
• Vomiting: Approximately 10-20% of participants
• Constipation: Approximately 10-15% of participants
• Decreased appetite: Common and expected given the mechanism of action

Less Common but Notable Effects

• Increased heart rate: Small elevations in resting heart rate were observed, consistent with other GLP-1 class medications
• Injection site reactions: Mild redness or itching at injection sites
• Fatigue: Reported by some participants, particularly during dose escalation

Most adverse events were mild to moderate and occurred primarily during the dose escalation phase. Proper titration — starting at a low dose and gradually increasing — was associated with better tolerability (Jastreboff et al., 2023).

Full safety data from Phase 3 trials will be essential for understanding the long-term risk profile, including any rare but serious adverse events.

Who Would Be a Good Candidate for Retatrutide?

Based on the clinical trial population and the medication’s mechanism, individuals who may benefit most from retatrutide once it becomes available include:

• Adults with a BMI of 30 or greater (obesity)
• Adults with a BMI of 27 or greater who have weight-related conditions such as type 2 diabetes, hypertension, dyslipidemia, or sleep apnea
• Individuals who have not achieved adequate results with semaglutide or tirzepatide
• Patients seeking greater weight loss than what current medications provide
• Individuals with metabolic dysfunction-associated steatohepatitis (MASH) given the glucagon receptor’s role in liver fat metabolism

Retatrutide may not be appropriate for individuals with a history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastrointestinal disorders, or a history of pancreatitis. These contraindications are expected to mirror those of existing GLP-1 medications, though the final prescribing information will be determined after FDA review.

Proven Weight Loss Peptides Available Now

While retatrutide works through the approval process, several highly effective, FDA-approved options are available today:

Semaglutide (Ozempic, Wegovy)

The most widely studied GLP-1 receptor agonist. The STEP trial program demonstrated an average weight loss of 14.9% over 68 weeks (Wilding et al., 2021). Semaglutide also has proven cardiovascular benefits, with the SELECT trial showing a 20% reduction in major adverse cardiovascular events (Lincoff et al., 2023).

Tirzepatide (Mounjaro, Zepbound)

A dual GLP-1/GIP receptor agonist that represents the closest currently available mechanism to retatrutide. The SURMOUNT-1 trial showed an average weight loss of 22.5% at the highest dose over 72 weeks (Jastreboff et al., 2022). Tirzepatide is an excellent option for patients seeking substantial weight loss while retatrutide remains unavailable.

Comprehensive Weight Loss Programs

Medication alone produces the best results when combined with lifestyle modifications. Evidence-based programs that integrate nutrition coaching, exercise guidance, behavioral support, and medical monitoring consistently outperform medication-only approaches.

What You Can Do Now to Prepare

Even if your goal is to eventually use retatrutide, there is no reason to delay taking action on your weight loss and metabolic health:

• Start with a proven medication. Beginning treatment with semaglutide or tirzepatide now allows you to make significant progress while retatrutide completes the approval process. You can transition to retatrutide later if it proves superior for your individual situation.
• Establish baseline health metrics. Comprehensive bloodwork, body composition analysis, and metabolic assessment now creates a benchmark for measuring future progress.
• Build sustainable habits. The lifestyle foundation you create now — nutrition, exercise, sleep, stress management — will amplify the results of any medication, including retatrutide.
• Work with a qualified provider. Establishing a relationship with a medical team experienced in metabolic health ensures you have trusted guidance when new treatments become available.

How Rewind Anti-Aging Can Help

At Rewind Anti-Aging, we stay at the forefront of metabolic health and weight loss treatments. Our team can help you:

• Evaluate your options. We assess your health profile, goals, and history to recommend the most appropriate current treatment.
• Access proven treatments today. We prescribe FDA-approved semaglutide and tirzepatide through our peptide therapy programs with personalized dosing and comprehensive monitoring.
• Stay informed on retatrutide. We track clinical trial progress and regulatory developments so our patients have access to new treatments as soon as they become available.
• Build a comprehensive plan. Our programs integrate medication with nutrition coaching, exercise guidance, and ongoing medical support for sustainable results.

Conclusion

Retatrutide represents a genuinely exciting advance in obesity medicine. The Phase 2 data showing 24.2% body weight loss in 48 weeks through a novel triple-agonist mechanism is unprecedented. However, the medication is still in clinical trials, and access through legitimate channels remains limited.

The most important takeaway is that you do not need to wait for retatrutide to take action. Highly effective, FDA-approved treatments like semaglutide and tirzepatide are available today and can produce transformative results. Starting treatment now puts you in the best possible position — whether you continue with a current medication or transition to retatrutide when it becomes available.

If you are interested in exploring your weight loss options, Rewind Anti-Aging of Miami offers comprehensive, medically supervised programs designed for lasting results. Book a consultation with our team to discuss which treatment is right for you.

Related Articles

• Retatrutide Dosage: A Complete Guide to Titration
• How Does Retatrutide Work? The Triple-Action Peptide Explained
• Retatrutide vs Tirzepatide: Which Peptide Is Better?

---

Want to start losing weight while retatrutide completes trials? Rewind Anti-Aging of Miami offers proven medical weight loss programs with semaglutide, tirzepatide, and other advanced therapies available today. Schedule a consultation →

This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational medication not yet approved by the FDA. Always consult with a qualified healthcare provider before starting any weight loss treatment.

References

1. Jastreboff, A. M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. The New England Journal of Medicine, 389(6), 514-526.
2. Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial. The Lancet, 402(10401), 529-544.
3. Campbell, J. E., & Drucker, D. J. (2015). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism, 22(6), 956-970.
4. Pocai, A. (2014). Action and therapeutic potential of oxyntomodulin. Molecular Metabolism, 3(3), 241-251.
5. Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). The New England Journal of Medicine, 384(11), 989-1002.
6. Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). The New England Journal of Medicine, 389(24), 2221-2232.
7. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). The New England Journal of Medicine, 387(4), 327-340.